| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1668* | 2020 |
| Whole-genome landscape of pancreatic neuroendocrine tumours A Scarpa, DK Chang, K Nones, V Corbo, AM Patch, P Bailey, RT Lawlor, ... Nature 543 (7643), 65-71, 2017 | 839 | 2017 |
| Whole-genome landscape of pancreatic neuroendocrine tumours A Scarpa, DK Chang, K Nones, V Corbo, AM Patch, P Bailey, RT Lawlor, ... Nature 543 (7643), 65-71, 2017 | 831 | 2017 |
| Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, ... Nature genetics 45 (12), 1470-1473, 2013 | 689 | 2013 |
| DNA qualification workflow for next generation sequencing of histopathological samples M Simbolo, M Gottardi, V Corbo, M Fassan, A Mafficini, G Malpeli, ... PloS one 8 (6), e62692, 2013 | 328 | 2013 |
| Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations CP Wardell, M Fujita, T Yamada, M Simbolo, M Fassan, R Karlic, P Polak, ... Journal of hepatology 68 (5), 959-969, 2018 | 310 | 2018 |
| Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups M Simbolo, M Fassan, A Ruzzenente, A Mafficini, LD Wood, V Corbo, ... Oncotarget 5 (9), 2839, 2014 | 209 | 2014 |
| Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for … M Simbolo, A Mafficini, KO Sikora, M Fassan, S Barbi, V Corbo, ... The Journal of pathology 241 (4), 488-500, 2017 | 195 | 2017 |
| A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics A Sadanandam, S Wullschleger, CA Lyssiotis, C Grötzinger, S Barbi, ... Cancer discovery 5 (12), 1296-1313, 2015 | 162 | 2015 |
| MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma A Lampis, P Carotenuto, G Vlachogiannis, L Cascione, S Hedayat, ... Gastroenterology 154 (4), 1066-1079. e5, 2018 | 111 | 2018 |
| Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients A Ruzzenente, M Fassan, S Conci, M Simbolo, RT Lawlor, C Pedrazzani, ... Annals of surgical oncology 23, 1699-1707, 2016 | 101 | 2016 |
| BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing A Mafficini, M Simbolo, A Parisi, B Rusev, C Luchini, I Cataldo, E Piazzola, ... Oncotarget 7 (2), 1076, 2016 | 95 | 2016 |
| Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations M Simbolo, S Barbi, M Fassan, A Mafficini, G Ali, C Vicentini, N Sperandio, ... Journal of Thoracic Oncology 14 (9), 1651-1661, 2019 | 88 | 2019 |
| Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 NSCLC M Moro, E Caiola, M Ganzinelli, E Zulato, E Rulli, M Marabese, ... Journal of Thoracic Oncology 13 (11), 1692-1704, 2018 | 86 | 2018 |
| High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas M Simbolo, C Mian, S Barollo, M Fassan, A Mafficini, D Neves, ... Virchows archiv 465, 73-78, 2014 | 76 | 2014 |
| High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers M Fassan, M Simbolo, E Bria, A Mafficini, S Pilotto, P Capelli, ... Gastric cancer 17, 442-449, 2014 | 71 | 2014 |
| Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm G Pelosi, F Bianchi, E Dama, M Simbolo, A Mafficini, A Sonzogni, S Pilotto, ... Virchows Archiv 472, 567-577, 2018 | 66 | 2018 |
| Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex A Gkountakos, S Pilotto, A Mafficini, C Vicentini, M Simbolo, M Milella, ... Carcinogenesis 39 (8), 971-980, 2018 | 63 | 2018 |
| Next-generation histopathologic diagnosis: a lesson from a hepatic carcinosarcoma C Luchini, P Capelli, M Fassan, M Simbolo, A Mafficini, F Pedica, ... Journal of clinical oncology: official journal of the American Society of …, 2014 | 55 | 2014 |
| PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer M Milella, I Falcone, F Conciatori, S Matteoni, A Sacconi, T De Luca, ... Scientific reports 7 (1), 43013, 2017 | 54 | 2017 |
Aldo ScarpaProfessor of Pathology, University of VeronaVerified email at univr.it
